THERAPEUTIC CLASS

Alemtuzumab to Treat Refractory Autoimmune Hemolytic Anemia or Thrombocytopenia in Chronic Lymphocytic Leukemia

---

Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP) are recognized complications of chronic lymphocytic leukemia (CLL) that can be life-threatening if not managed appropriately. Conventional therapies for these autoimmune disorders, such as corticosteroids, splenectomy, and immunosuppressive agents, may not induce complete
resolution in all patients, and relapses are common. In recent years, monoclonal antibodies such as alemtuzumab
and rituximab, already used successfully for the management of lymphoproliferative disorders, have been shown to be effective in the treatment of a range of autoimmune disorders.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Oncology

Specific Detail Info

Current Hematologic Malignancy Reports 2009, 4:47–53

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment